A significant number of Phase 2 participants achieved clinically meaningful weight loss at 4mg and 8mg
People who participated in the trial either took a nine milligram or 12 milligram dose of retatrutide once a week for 68 weeks
A lot of patients wind up in a maxillofacial consult for the first time in their adult lives after a year on a GLP-1, and theyre not imagining things
Insulin and leptin levels drop precipitously, both of which have downstream effects on follicular health
In a phase 2 clinical trial targeting obese individuals without type 2 diabetes (T2D), retatrutide dosed at 1 to 12 mg resulted in up to 24.2% weight loss over a 48-week treatment period, compared to 2.1% in the placebo group, and demonstrated a dose-dependent effect
This dramatic increase in weight reduction capabilities naturally leads to speculation around additional health benefits for multiple conditions, including diabetes, cardiovascular, sleep apnea, and others for which medical devices and procedures are often part of management and treatment regimens
